Delivery Order SPE2DR25D1100-SPE2DR26FCM8A
- Not listed
- The Defense Logistics Agency awarded a $11.9K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampul 2.5mL pharmaceutical product, with an ultimate completion date of July 28, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $10,334.40 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in respiratory care. This firm fixed-price delivery order, awarded on July 17, 2025, with an ultimate completion date of July 18, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,356.71 to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampule 2.5ml pharmaceutical supplies. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 18, 2025, issued on September 17, 2025. The contract will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $40,007.44 to supply Pulmozyme 1 mg/ml ampules (2.5 ml units), a pharmaceutical product used in respiratory care. This firm fixed-price delivery order, awarded on August 12, 2025, with completion scheduled for August 13, 2025, was competitively awarded without set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $36,747.91 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampuls (2.5 ml units) with an ultimate completion date of October 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $2,583.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in the treatment of cystic fibrosis. The contract, awarded on October 24, 2025, with an ultimate completion date of October 27, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This delivery order was competitively awarded without...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Pulmozyme 1 mg/ml ampul 2.5ml pharmaceutical product, with a ceiling value of $8,168.13 under a firm fixed-price contract type. This delivery order represents a non-set-aside award issued to the vendor's Conshohocken, Pennsylvania location and is scheduled for ultimate completion by October 22, 2025. The contract is a child award under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampul 2.5mL, a pharmaceutical product used in treating cystic fibrosis. This firm fixed-price delivery order, valued at $48,360.96, was competitively awarded without set-aside designation and carries an ultimate completion date of October 22, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $9.68K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampules (2.5 mL units) on July 23, 2025, with completion expected by July 24, 2025. This is a firm fixed-price, non-set-aside contract performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99M vehicle extending through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml units) under a firm fixed-price contract with a ceiling value of $10,076.66. The order was competitively awarded without set-aside designation and is scheduled for completion by September 16, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCM8ADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $12,871.03 to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product for pulmonary disease treatment. The contract was competitively awarded without set-aside designation under a firm fixed price arrangement, with completion scheduled for November 6, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in Conshohocken, PA 19428. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The prime IDC serves as a comprehensive pharmaceutical support vehicle enabling the company to supply medications and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp's extensive federal contract portfolio demonstrates its established capability to fulfill diverse federal medical procurement requirements across multiple therapeutic domains for military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.9k | 11/5/25 |